ThinkEquity's Rating of Regentis Biomaterials on 3/2/2026

On March 2, 2026, ThinkEquity updated its outlook on Regentis Biomaterials (NYSEAMERICAN:RGNT) with the action "Upgrade", setting a "Strong-Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from ThinkEquity

DateCompanyAction
6/15/2026
Quoin Pharmaceuticals, Ltd. Sponsored ADR stock logo
QNRX
Quoin Pharmaceuticals
Initiated Coverage
6/15/2026
Greenland Energy Co stock logo
GLND
Greenland Energy
Initiated Coverage
6/8/2026
GameSquare Holdings, Inc. stock logo
GAME
GameSquare
Initiated Coverage
5/26/2026
Atlas Technical Consultants, Inc. stock logo
ATCX
Atlas Technical Consultants
Initiated Coverage
5/4/2026
Bimergen Energy Corporation stock logo
BESS
Bimergen Energy
Upgrade
1/20/2026
Off The Hook Ys Inc. stock logo
NXB
Off The Hook Ys
Upgrade
More Ratings From ThinkEquity